Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Melphalan.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Melphalan.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Melphalan.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Melphalan is combined with Anthrax immune globulin human.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Melphalan.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Melphalan is combined with Bacillus calmette-guerin substrain connaught live antigen.
Advertisement
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Melphalan is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Melphalan.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Melphalan.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.
Carmustine
The risk or severity of adverse effects can be increased when Melphalan is combined with Carmustine.
Clozapine
The risk or severity of adverse effects can be increased when Melphalan is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Melphalan.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Melphalan.
Cyclosporine
Melphalan may increase the nephrotoxic activities of Cyclosporine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Melphalan.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Melphalan.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Melphalan.
Digoxin
Digoxin may decrease the cardiotoxic activities of Melphalan.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Melphalan.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.
Fingolimod
Melphalan may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Melphalan is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Melphalan is combined with Hepatitis B Vaccine (Recombinant).
Leflunomide
The risk or severity of adverse effects can be increased when Melphalan is combined with Leflunomide.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Nalidixic Acid is combined with Melphalan.
Natalizumab
The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Melphalan.
Ouabain
Ouabain may decrease the cardiotoxic activities of Melphalan.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Melphalan.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Melphalan.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Melphalan.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Melphalan.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Melphalan is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Melphalan.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Melphalan.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Melphalan is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Melphalan is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Melphalan is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Melphalan.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Melphalan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Melphalan may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Melphalan.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Melphalan is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Melphalan is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Melphalan is combined with Varicella Zoster Vaccine (Live/Attenuated).
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Melphalan is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Melphalan is combined with Yellow Fever Vaccine.
